Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00287
|
|||||
| Drug Name |
Resveratrol
|
|||||
| Synonyms |
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; (E)-5-(p-Hydroxystyryl)resorcinol; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; (E)-resveratrol; 3,4',5-Stilbenetriol; 3,4',5-Trihydroxy-trans-stilbene; 3,4',5-Trihydroxystilbene; 3,4',5-trihydroxy-stilbene; 3,5,4'-Trihydroxy-trans-stilbene; 3,5,4'-Trihydroxystilbene; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CU-01000001503-3; Cis-resveratrol; KSC-10-164; KUC104385N; PREVENTION 8 (RESVERATROL); R 5010; RM-1812; Resveratrol-3-sulfate; Resvida; SRT 501; SRT-501; SRT501; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; Trans-3,4′,5-Trihydroxystilbene; Trans-3,4',5-trihydroxystilbene; Trans-resveratrol
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Colorectal cancer [ICD11: 2B91] | Discontinued in Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C14H12O3
|
|||||
| Canonical SMILES |
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
|
|||||
| InChI |
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
|
|||||
| InChIKey |
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
|
|||||
| CAS Number |
CAS 375823-41-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 228.24 | Topological Polar Surface Area | 60.7 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10299643
, 10321586
, 11537676
, 12015089
, 14822845
, 17388746
, 17405667
, 22388006
, 24278055
, 24715042
, 24860876
, 26512266
, 26612338
, 26679661
, 26697115
, 26736772
, 26747076
, 26747077
, 26751586
, 26751587
, 26759440
, 29204531
, 36887952
, 458391
, 46386962
, 46493745
, 46504705
, 47291249
, 47515445
, 47589112
, 47959898
, 48035263
, 48035264
, 48185110
, 48185111
, 48334633
, 48424038
, 48425593
, 49661756
, 49698529
, 49734167
, 49833229
, 584207
, 611168
, 6374
, 7890614
, 8145576
, 837578
, 855986
, 866574
|
|||||
| ChEBI ID |
CHEBI45713
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
| References | ||||||
| 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018787) | |||||
| 2 | The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.